istock-508496956cosmin4000

cosmin4000 / iStockphoto.com

27 September 2018Americas

IP and personalised medicine: a tailor-made approach

In 2017, the US Food and Drug Administration (FDA) approved a record 16 new personalised medicines, according to the “Personalized Medicine at FDA: 2017 Progress Report”. From 2014 to 2017, more than one in every four drugs the agency approved was a personalised medicine.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

LSIPR 50 2018: Personalised medicine: the way forward

13 July 2018 BMS’s teams are working to answer key questions and more intimately understand the interplay between the immune system and cancer, Paul Golian, vice president and assistant counsel of IP at BMS, tells LSIPR.

article

Personalised medicine in Europe: is the patent system keeping up?

19 February 2014 The rise of so-called personalised medicine presents new challenges and opportunities for drugs companies, says Robert Andrews.

More on this story

LSIPR 50 2018: Personalised medicine: the way forward

13 July 2018 BMS’s teams are working to answer key questions and more intimately understand the interplay between the immune system and cancer, Paul Golian, vice president and assistant counsel of IP at BMS, tells LSIPR.

article

Personalised medicine in Europe: is the patent system keeping up?

19 February 2014 The rise of so-called personalised medicine presents new challenges and opportunities for drugs companies, says Robert Andrews.

More on this story

LSIPR 50 2018: Personalised medicine: the way forward

13 July 2018 BMS’s teams are working to answer key questions and more intimately understand the interplay between the immune system and cancer, Paul Golian, vice president and assistant counsel of IP at BMS, tells LSIPR.

article

Personalised medicine in Europe: is the patent system keeping up?

19 February 2014 The rise of so-called personalised medicine presents new challenges and opportunities for drugs companies, says Robert Andrews.

More features

Bayer gains exclusive licence for heart drug in Japan

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

McGuireWoods expands team with ex-Novo Nordisk GC

Paul, Weiss swoops for senior duo from Weil, Gotshal

UPC bans Meril Life Sciences from selling infringing heart valve

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic

Kathi Vidal to rejoin previous firm as partner following USPTO departure

GSK triumphs in EPO appeal, revoking Pfizer patent